Thursday 8 December 2011

Australian Securities Exchange Announcement

ADDITIONAL COVERED LIVES
EXPANDED U.S. COVERAGE FOR L-DEX TESTING

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“ImpediMed” or “the Company”) reports today expanded U.S. coverage for the use of its L-Dex® medical device as an aid in the clinical assessment of unilateral lymphoedema of the arm in females. The first private Insurer to confirm coverage under policy is a key Pennsylvania based health plan that has been using the technology in its women’s hospital system for over 12 months. The health plan provides healthcare insurance to over 1.6 million covered lives in western Pennsylvania. With this plan the Company’s cumulative total of covered lives has expanded to 13.8 million.

In commenting on the coverage, Greg Brown, CEO said, “It’s gratifying to see such a prestigious and progressive, academic medical center embrace BIS technology as a part of their breast cancer program. The health plan’s support of the clinical service demonstrates their confidence in the pre-emptive model and the ability to control the cost of chronic care by covering for L-Dex testing to aid clinicians in their clinical assessment of lymphoedema.”

Greg Brown
CEO

ENDS
For further information contact:

Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127

L-Dex® is a trademark of ImpediMed Limited.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

The L-Dex scale is a tool to aid in the clinical assessment of unilateral lymphoedema of the arm in women by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed
ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit: www.impedimed.com.au